Patent ID: 8324152

Claim:
A method for treating atherosclerosis in a subject, which comprises a continuous subcutaneous or transcutaneous administration to said subject of a therapeutically effective amount of at least one epitope for a period of time within the range of 7 to 30 days and at a daily dose within the range of 0.05 to 5000 μg per kg body weight per day, wherein the at least one epitope is administered for a period of time and at a daily dose, which are sufficient to induce a specific regulatory immune response, and wherein said epitope is a synthetic peptide derived from apolipoprotein B-100 (apoB-100), wherein said synthetic peptide is selected from the group consisting of: KTTKQSFDLSVKAQYKKNKH (SEQ ID NO: 14); FPDLGQEVALNANTKNQKIR (SEQ ID NO: 37); and SEQ ID NO: 14 or 37 modified to mimic a modification of apoB-100 protein that may occur during oxidation or non-oxidative modification of LDL, selected from the group consisting of oxidation by exposure to copper, oxidation after aldehyde-modification or acetylation.